Medite Financial Statements From 2010 to 2025
| MDIT Stock | USD 0.0001 0.00 0.00% |
Check Medite Cancer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medite Cancer's main balance sheet or income statement drivers, such as , as well as many indicators such as . Medite financial statements analysis is a perfect complement when working with Medite Cancer Valuation or Volatility modules.
Medite |
Medite Cancer Diagnostics Company Return On Asset Analysis
Medite Cancer's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Medite Cancer Return On Asset | -0.14 |
Most of Medite Cancer's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medite Cancer Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Medite Cancer Diagnostics has a Return On Asset of -0.1368. This is 98.44% lower than that of the Health Care Equipment & Supplies sector and 99.53% lower than that of the Health Care industry. The return on asset for all United States stocks is 2.29% lower than that of the firm.
Medite Cancer Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medite Cancer's current stock value. Our valuation model uses many indicators to compare Medite Cancer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medite Cancer competition to find correlations between indicators driving Medite Cancer's intrinsic value. More Info.Medite Cancer Diagnostics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medite Cancer's earnings, one of the primary drivers of an investment's value.About Medite Cancer Financial Statements
Medite Cancer shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Medite Cancer investors may analyze each financial statement separately, they are all interrelated. The changes in Medite Cancer's assets and liabilities, for example, are also reflected in the revenues and expenses on on Medite Cancer's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.